<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03339336</url>
  </required_header>
  <id_info>
    <org_study_id>802NP206</org_study_id>
    <secondary_id>2017-000991-27</secondary_id>
    <nct_id>NCT03339336</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy</brief_title>
  <official_title>A Phase 2 Placebo-Controlled, Double-Blind, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 (Vixotrigine) in Treating Pain Experienced by Subjects With Confirmed Small Fiber Neuropathy That is Idiopathic or Associated With Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of BIIB074 in treating pain
      experienced by participants with confirmed small fiber neuropathy (SFN) that is idiopathic or
      associated with diabetes mellitus. A secondary endpoint that relates to the primary objective
      is the change from Randomization to Week 12 of the double-blind period in mean average daily
      pain score.

      The secondary objectives of this study are to evaluate the effect on worst pain, neuropathic
      pain quality, sleep interference due to pain, patient global impression, use of rescue
      medication, and SFN symptoms in participants treated with BIIB074; to investigate the safety
      and tolerability of BIIB074 in participants with SFN; and to characterize the
      pharmacokinetics (PK) of BIIB074 in participants with SFN.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2018</start_date>
  <completion_date type="Anticipated">May 6, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 6, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Weekly Mean Average Daily Pain (ADP) Score</measure>
    <time_frame>Baseline and Week 12 of the Double-Blind Period</time_frame>
    <description>Participants will rate their ADP using an 11-point Numerical Rating Scale (NRS) (0=no pain and 10=worst possible pain) and record their score in an electronic diary (eDiary). Weekly mean ADP scores for Baseline (the 5 days prior to the first dose of study treatment in the open-label run-in period) and Week 12 (the 7 days prior to the visit at the end of Week 12) will be derived from the ADP scores and calculated as the mean of the daily scores over the last 7 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Randomization in Weekly Mean ADP Score</measure>
    <time_frame>Randomization and Week 12 of the Double-Blind Period</time_frame>
    <description>Participants will rate their ADP using an 11-point NRS (0=no pain and 10=worst possible pain) and record their score in an eDiary. Weekly mean ADP scores for Randomization (the 7 days prior to the first dose of study treatment in the double-blind period) and Week 12 (the 7 days prior to the visit at the end of Week 12) will be derived from the ADP scores and calculated as the mean of the daily scores over the last 7 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Weekly Mean Worst Daily Pain (WDP) Score</measure>
    <time_frame>Baseline and Week 12 of the Double-Blind Period</time_frame>
    <description>Participants will rate their WDP using an 11-point NRS (0=no pain and 10=worst possible pain) and record their score in an eDiary. Weekly mean WDP scores for Baseline (the 5 days prior to the first dose of study treatment in the open-label run-in period) and Week 12 (the 7 days prior to the visit at the end of Week 12) will be derived from the WDP scores and calculated as the mean of the daily scores over the last 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Weekly Mean Sleep Interference Numerical Rating Scale (S-NRS)</measure>
    <time_frame>Baseline and Week 12 of the Double-Blind Period</time_frame>
    <description>Participants will rate their S-NRS using an 11-point NRS (0=pain does not interfere with sleep and 10= pain completely interferes with sleep) and record their score in an eDiary. Weekly mean S-NRS scores for Baseline (the 5 days prior to the first dose of study treatment in the open-label run-in period) and Week 12 (the 7 days prior to the visit at the end of Week 12) will be derived from the daily S-NRS scores and calculated as the mean of the daily scores over the last 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Neuropathic Pain Symptom Inventory (NPSI) Total Score and Sum Score</measure>
    <time_frame>Baseline and Week 12 of Double-Blind Period</time_frame>
    <description>Participant will use the NPSI questionnaire to rate different symptoms of neuropathic pain. The NPSI includes ten items related to different pain descriptors (e.g. burning and pressure) that are rated on an 11-point NRS (0=no symptoms to 10=worst symptoms imaginable). A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with at least a 2-point Reduction from Baseline in Weekly Mean ADP</measure>
    <time_frame>Baseline and Week 12 of the Double-Blind Period</time_frame>
    <description>Participants will rate their ADP using an 11-point NRS (0=no pain and 10=worst possible pain) and record their score in an electronic diary (eDiary). Weekly mean ADP scores for Baseline (the 5 days prior to the first dose of study treatment in the open-label run-in period) and Week 12 (the 7 days prior to the visit at the end of Week 12) will be derived from the ADP scores and calculated as the mean of the daily scores over the last 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with at least a 30% Reduction from Baseline in Weekly Mean ADP</measure>
    <time_frame>Baseline and Week 12 of Double-Blind Period</time_frame>
    <description>Participants will rate their ADP using an 11-point NRS) (0=no pain and 10=worst possible pain) and record their score in an electronic diary (eDiary). Weekly mean ADP scores for Baseline (the 5 days prior to the first dose of study treatment in the open-label run-in period) and Week 12 (the 7 days prior to the visit at the end of Week 12) will be derived from the ADP scores and calculated as the mean of the daily scores over the last 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Amount of Rescue Medication</measure>
    <time_frame>Weekly from Baseline to Week 12 of the Double-Blind Period</time_frame>
    <description>Use of rescue medication (paracetamol/acetaminophen) will be monitored and dosage will be recorded on a daily basis by the participant using an electronic Diary (eDiary). Mean weekly amount of rescue medication used for neuropathic pain during the double-blind period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC)</measure>
    <time_frame>Week 12 of the Double-Blind Period</time_frame>
    <description>PGIC is a 7-point self-administered scale that depicts changes in a participant's overall status. Participants will rate their change as &quot;1=very much improved,&quot; &quot;2=much improved,&quot; &quot;3=minimally improved,&quot; &quot;4=no change,&quot; &quot;5=minimally worse,&quot; &quot;6=much worse,&quot; or &quot;7=very much worse.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Brief Pain Inventory-Short Form (BPI-SF) Interference Score</measure>
    <time_frame>Baseline and Week 12 of the Double-Blind Period</time_frame>
    <description>The BPI-SF is a 7-item self-administered questionnaire that measures how much pain has interfered with daily functioning. Participants will rate the level of pain interference on daily functioning on an 11-point NRS where 0=does not interfere and 10=completely interferes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) During Double-Blind Period</measure>
    <time_frame>Week 5 to Week 17</time_frame>
    <description>AEs: any sign, symptom, or diagnosis/disease that is unfavorable or unintended, that is new, or if pre-existing, worsens in participants administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. SAEs: an event that results in death; an event that, in the view of the investigator, places the participant at immediate risk of death (a life-threatening event); an outcome that results in a congenital anomaly/birth defect diagnosed in a child of a participant; an event that requires or prolongs inpatient hospitalization; an event that results in persistent or significant disability/incapacity. Any other medically important event that, in the opinion of the investigator, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve at Steady State</measure>
    <time_frame>Week 1, 3, 5, 9, 13 and 17 prior to dosing and 1 to 2 hours after dosing, and at Day 123 (Follow-up clinic visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) at Steady State</measure>
    <time_frame>Week 1, 3, 5, 9, 13 and 17 prior to dosing and 1 to 2 hours after dosing, and at Day 123 (Follow-up clinic visit)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Small Fiber Neuropathy</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>BIIB074 350 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 350 mg tablets orally BID Double-Blind Treatment Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIIB074 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 200 mg tablets orally BID Double-Blind Treatment Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 placebo-matching tablets orally BID Double-Blind Treatment Period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB074</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>BIIB074 200 mg</arm_group_label>
    <arm_group_label>BIIB074 350 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. This study will be conducted in subjects who have had a diagnosis of at least probable
             SFN, length-dependent distribution, for 6 months and ≤10 years prior to screening,
             defined as a history of the symptoms and clinical signs based on discussions at the
             ACTTION CONCEPPT meeting on diagnosis of SFN, Washington, DC March 2018, and confirmed
             by intraepidermal nerve fiber density (IENFD) values, and weekly mean average daily
             pain (ADP) score of ≥5 and ≤9 on an 11-point Pain Intensity Numeric Rating Scale
             (PI-NRS) over the last 7 days of prior to the Screening visit.

          2. In addition to these criteria, subjects with diabetes will be required to have HbA1c
             ≤11%, treated with oral hypoglycemics and/or subcutaneous insulin or diet, no evidence
             of ulcers, advanced retinopathy (defined as greater than State 3 [moderate
             non-proliferative diabetic retinopathy]) (DCCT/EDIC Research Group 2017), severe
             nephropathy, or clinically significant obstructive atherosclerotic disease or current
             class IV heart failure to be eligible for the study.

        Key Exclusion Criteria:

          1. Previous exposure to BIIB074 (formerly known as CNV1014802 or GSK1014802).

          2. Use of capsaicin patch within 3 months prior to Screening.

          3. Unable or unwilling to discontinue concomitant medications for SFN pain prior to Day
             1.

          4. Unable or unwilling to comply with the prohibited concomitant medication restrictions,
             including but not limited to UDP-glucuronosyltransferase (UGT) inducers and
             inhibitors, monoamine oxidase inhibitors (MAOIs), and Nav blockers.

          5. Use of over-the-counter medications, vitamin and mineral supplements, herbal remedies
             (including St. John's wort), dietary supplements, or foods (including grapefruit
             juice) that affect and UGTs.

          6. Unable or unwilling to discontinue medications that are P-glycoprotein substrates with
             a narrow therapeutic index, including but not limited to digoxin.

          7. History of hemophilia or Von Willebrand's disease, or use of anticoagulants that may
             result in bleeding risk during the skin biopsy.

          8. Any contraindication, as determined by the Investigator, to performing a skin biopsy
             for intraepidermal nerve fiber analysis.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Biogen Clinical Trial Center</last_name>
    <phone>866-633-4636</phone>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Biogen Clinical Trial Center</last_name>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Byala</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMHAT 'Dr Georgi Stranski' EAD</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Kraus</last_name>
      <phone>604 875 4111</phone>
      <phone_ext>22950</phone_ext>
      <email>Deborah.Kraus@vch.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Ng</last_name>
      <email>eduardo.ng@uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>Vera Bril</last_name>
      <phone>+416 340 3315</phone>
    </contact_backup>
    <investigator>
      <last_name>Vera Bril</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Recherche Médicale St-Jérôme Inc.</name>
      <address>
        <city>St-Jerome</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanick Sardin-Laframboise</last_name>
      <phone>450431102033</phone>
      <email>ysardin@stjerome-medicalresearch.ca</email>
    </contact>
    <investigator>
      <last_name>Yves Pesant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kingston</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winnipeg</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Vlckova</last_name>
      <phone>+420 532 232 503</phone>
      <email>vlckova.eva@fnbrno.cz</email>
    </contact>
    <investigator>
      <last_name>Eva Vlckova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice u sv. Anny v Brne</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduard Minks</last_name>
      <phone>543 18 2881</phone>
      <email>eduard.minks@fnusa.cz</email>
    </contact>
    <investigator>
      <last_name>Eduard Minks</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava</name>
      <address>
        <city>Ostrava-Poruba</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Brodova</last_name>
      <email>brodova@ahas.cz</email>
    </contact>
    <contact_backup>
      <last_name>Michal Bar</last_name>
      <email>Michal.Bar@fno.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Michal Bar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemocnice Pardubickeho kraje a.s. Pardubicka nemocnice</name>
      <address>
        <city>Pardubice</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Edvard Ehler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radka Maierova, Study Nurse</last_name>
      <phone>00420 22443 6896</phone>
    </contact>
    <investigator>
      <last_name>Veronika Potockova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>OUH</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Soren Sindrup</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brest</city>
        <state>Finistere</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barillar Edwige, Study Coordinator</last_name>
      <email>edwige.barillar@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint Etienne - Hôpital Nord</name>
      <address>
        <city>Saint Priest En Jarez</city>
        <state>Loire</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Christelle Creach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Salengro - CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celine Tard</last_name>
      <email>celine.tard@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Celine Tard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clermond Ferrand - Hopital Gabriel Montpied</name>
      <address>
        <city>Clermont Ferrand</city>
        <state>Puy De Dome</state>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré - Boulogne-Billancourt</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Nadine Attal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Petit</last_name>
      <phone>+33 161697048</phone>
    </contact>
    <investigator>
      <last_name>Catherine Petit</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Boucle</last_name>
      <phone>01 49 87 37 88</phone>
      <email>caroline.boucle@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Le Creusot</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupement Hospitalier Sud - Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>david.adams@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>David Adams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nice - Hôpital de l'Archet 1</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Romettino</last_name>
      <phone>+33 04 92 03 84 81</phone>
      <email>ROMETTINO.S@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Michel Lanteri Minet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Simoneau</last_name>
      <email>guy.simoneau@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Damien Sene</last_name>
      <email>damien.sene@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Damien Sene</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research</name>
      <address>
        <city>Böblingen</city>
        <state>Baden-Württemberg</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research</name>
      <address>
        <city>Westerstede</city>
        <state>Niedersachsen</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research</name>
      <address>
        <city>Muenster</city>
        <state>Nord Rhein Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>49 251 9352 321</phone>
    </contact>
    <investigator>
      <last_name>Rose Ludger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Diabeteszentrum Dortmund Dr.med. Klaus Busch</name>
      <address>
        <city>Dortmund</city>
        <state>Nordrhein Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Klaus Busch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hausarzt- und Diabetologische Schwerpunktpraxis</name>
      <address>
        <city>Lage</city>
        <state>Sachsen Anhalt</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+4934441990299</phone>
    </contact>
    <investigator>
      <last_name>Dr Karsten Milek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zentrum fur Klinische Forschung</name>
      <address>
        <city>Bad Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>forschungszentrum@dr-schoell.de</email>
    </contact>
    <investigator>
      <last_name>Dr Irma Scholl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Neurologie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>info@dienervenärzte.de</email>
    </contact>
    <contact_backup>
      <last_name>Kathrin Wittenberg</last_name>
      <email>k.wittenberg@dienervenärzte.de</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Gratz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Fleischer</last_name>
      <email>Michael.Fleischer@uk-essen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diabetologische Schwerpunktpraxis Harburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>dr.paschen@diabetologie-harburg.de</email>
    </contact>
    <investigator>
      <last_name>Dr Bjoern Paschen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DKD Helios Klinik Wiesbaden</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Muller</last_name>
      <phone>+49 611 577 652</phone>
      <email>Martina.Muller4@helios-gesundheit.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wurzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>AHEPA General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baja</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaz</name>
      <address>
        <city>Bekescsaba</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>botyik@bmkk.eu</email>
    </contact>
    <contact_backup>
      <last_name>Dr Balasz Botyik</last_name>
      <email>balazsbotyik@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dr Zoltan Taybani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNO Medical Trials Kft.</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnes Orlos</last_name>
      <phone>+361 796 9812</phone>
      <email>agnes.orlos@unomedicaltrials.hu</email>
    </contact>
    <contact_backup>
      <email>kovacs.krisztina@otvkft.hu</email>
    </contact_backup>
    <investigator>
      <last_name>Krisztina Kovacs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi Mor Oktato Korhaz</name>
      <address>
        <city>Kaposvar</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>´+36 30 9768 885</phone>
    </contact>
    <investigator>
      <last_name>Dr Laszlo Deak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Massimiliano Filosto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Univeraitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Siciliano</last_name>
      <email>g.siciliano@med.unipi.it</email>
    </contact>
    <investigator>
      <last_name>Gabriele Siciliano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Campus Bio-Medico di Roma</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariagrazia Rossi</last_name>
      <email>m.rossi@unicampus.it</email>
    </contact>
    <investigator>
      <last_name>Vincenzo Di Lazzaro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Telese Terme</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC, Locatie AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC+</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chorzow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna Zalejska-Kuźniak</last_name>
      <phone>´0048 691 847 596</phone>
      <email>kasia.kuzniak@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Grazyna Popenda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PRATIA MCM Kraków</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Szklener</last_name>
      <phone>+48 666 165 103</phone>
      <email>sebastianszklener@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oswiecim</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praktyka Lekarska Ewa Krzyzagorska</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Krzyzagorska</last_name>
      <phone>+48 504 211 981</phone>
      <email>ewa.krzyzagorska@cs.put.poznan.pl</email>
    </contact>
    <investigator>
      <last_name>Ewa Krzyzagorska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justyna Pawlowska</last_name>
      <email>Justyna.Pawlowska@bioclinica.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regionalna Poradnia Diabetologiczna Zytkiewicz-Jaruga,Stasinska</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jadwiga KARCZEWICZ-JANOWSKA</last_name>
      <phone>4871 343 58 81</phone>
      <email>teresa1411@op.pl</email>
    </contact>
    <investigator>
      <last_name>Teresa Stasinska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34 96 591 3713</phone>
    </contact>
    <investigator>
      <last_name>Carmen Diaz Marin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34932607323</phone>
      <email>a.serrano@bellvitgehospital.cat</email>
    </contact>
    <investigator>
      <last_name>Dr Ancor Serrano Afonso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34 68 89 05 848</phone>
    </contact>
    <investigator>
      <last_name>Eduardo Aguera-Morales</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0034 9819 50332</phone>
    </contact>
    <investigator>
      <last_name>Julio Pardo Fernandez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>pedro.bermejo.v@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pedro Emilio Bermejo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Teresa Sevilla Mantecon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUV - Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carine Marucci</last_name>
      <email>carine.marucci@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Marc Suter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Lugano</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kantonspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ansgar Felbecker</last_name>
      <email>ansgar.felbecker@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Ansgar Felbecker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>d.selvarajah@sheffield.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Dr Dinesh Selvarajah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital</name>
      <address>
        <city>Ipswich</city>
        <state>Suffolk</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinical Reseach</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ipswich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Wesley</last_name>
      <phone>+0207 188 3237</phone>
      <email>Samuel.Wesley@gstt.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dhaval Trivedi</last_name>
      <phone>020 3299 7154</phone>
      <email>dhaval.trivedi1@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Robert Hadden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Pancras Clinical Research</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart Ratcliffe</last_name>
      <phone>+0203 865 1142</phone>
      <email>stuartratcliffe@stpancrasclinical.com</email>
    </contact>
    <contact_backup>
      <email>petrinaayerteygbeve@stpancrasclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Petrina Ayertey-Gbeve</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberley Allen-Philbey</last_name>
      <email>k.allen-philbey@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Aleksandar Radunovic</last_name>
      <phone_ext>0203 594 0637</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Aleksander Radunovic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Gallehawk</last_name>
      <phone>01865 234892</phone>
      <email>stephanie.gallehawk@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Davies</last_name>
      <phone>01792 530 888</phone>
      <email>abm.rd@wales.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Fiber Neuropathy</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

